Business Wire

Now, officially Cool! Price f(x) named “Gartner® Cool Vendor in Digital Commerce”

Share

Price f(x), a leader in Price Optimization & Management SaaS, has been named a “Cool Vendor in Digital Commerce” in the 2018 report by Gartner®, Inc.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005662/en/

Price f(x) is the pioneer of native Price Optimization & Management SaaS (“PO&M SaaS”) offering uniquely flexible, functionally broad and fast to implement solutions. In the report, Gartner® highlights Price f(x) as a true disruptor in this software segment through uncompromised customer-centric approach best reflected in the commercial offering of Pricing-as-a-Service (“PraaS™”). “We are devoted to simplicity, relevance and agility, but most importantly to commercial fairness. Our solution is designed, both technically and commercially, to quickly provide value to companies of any size, in any industry, in B2B, B2C as well as B2B2C. And offering all of that entirely free of implementation costs in our PraaS™ offering – truly is cool,” said Marcin Cichon, CEO of Price f(x).

According to Gartner®, “(…) the PraaS™ model, combined with contract terms as short as three months, shifts much of the project risk to the vendor and requires no capital expenditure by the customer. The total cost of a Price f(x) project can be less than one-quarter of that of its more established competitors . Gartner® clients report that this zero-capital-expenditure, low-risk offering is compelling, and have been pleased with project outcomes.”1.

“We are very happy that our unique commercial approach, focusing on the total elimination of customer risks related to adoption of our technology, and its full market impact has been recognized by Gartner®,” said Billy Graham, VP Ecosystem at Price f(x).

Since its market entry in late 2012, Price f(x) has been the fastest growing software company in the PO&M SaaS market. In 2017, Price f(x) introduced the “PFX Platform” and its front-end integration to the world’s leading CRM applications – Salesforce®, SAP Hybris C4C® and Microsoft Dynamics®. The decision to not just offer limited functionality Pricing Apps on top of those CRM solutions but to seamlessly mashup into them with powerful price optimization, promotion and rebate management as well as transactional pricing functionality, marks a new dimension in the Digital Commerce.

“Being named a Gartner® Cool Vendor means for us an undeniable market validation of our attractive commercial approach,” said Patrick Adams, SVP Commercial Excellence at Price f(x). “Our unprecedented model truly works both ways, providing our customers with unmatched value and acceleration in market adoption, while allowing us to scale up quickly to achieve profitable growth.”

One of Price f(x)’s many marquee customers Sonoco and valued partner Big Data Pricing will host together an online webinar How Change Management Drives Price Transformation Success on June 5th to demonstrate how “cool” technology can help in solution adoption and resulting change management success when implementing complex pricing solutions. We encourage everyone to register at https://go.pricefx.eu/sonoco-bdp-2018-webinar and get inspired by this true success story.

Gartner subscribers and clients can access the report here Gartner Cool Vendors in Digital Commerce .

1 Gartner, Inc., “Cool Vendors in Digital Commerce” by Mark Lewis, et al, on May 16, 2018.

Required Disclaimer

Gartner® does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner® research publications consist of the opinions of Gartner®'s research organization and should not be construed as statements of fact. Gartner® disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Price f(x)

Founded in 2011 in Germany, Price f(x) AG provides a full suite price optimization, management and CPQ SaaS solution based on a native cloud architecture, offering broad and flexible support across the entire price management lifecycle, including Price Strategy, Controlling, Setting, Optimization, and Realization. The solution is suitable for B2B and B2C as well as any industry facing the classical but also particular pricing challenges of commercial organizations of any size and geographical location. Price f(x)’s vision is to remain the leading SaaS pricing and CPQ solution provider through offering easy to use, fast to implement, flexible to adapt, risk-free and inexpensive, comprehensive solutions. Price f(x)’s business model is entirely based on satisfaction and loyalty of their customers versus enforcing long-term commitments.

Contact information

Price f(x)
Media and Investor Relations
Billy Graham, VP Ecosystem
+420 226 254 980
billy.graham@pricefx.eu

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu